Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes

• Published in: European journal of clinical pharmacology Vol. 37; no. 1; p. 33
• Main Authors: Heinz, G, Komjati, M, Korn, A, Waldhäusl, W
• Format: Journal Article
• Language: English
• Published: Germany 1989
• Subjects: 1-Deoxynojirimycin - analogs & derivatives; Adult; Aged; Blood Glucose - metabolism; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Diet; Dose-Response Relationship, Drug; Glucosamine - adverse effects; Glucosamine - analogs & derivatives; Glucosamine - therapeutic use; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Insulin - blood; Middle Aged; Time Factors
• ISSN: 0031-6970
• DOI: 10.1007/BF00609420

The dose-dependency of the effects of the alpha-glucosidase inhibitor Miglitol (Bay m 1099) was investigated in 8 Type II diabetic patients. Administration of increasing doses of Miglitol once daily in the morning on four consecutive days concomitantly with a standardized meal containing 50 g starch led to a dose-dependent reduction in the maximal increase in the postprandial blood glucose level and in postprandial incremental AUC of blood glucose. The latter was significant for 50, 100, 75 and 200 mg Miglitol. Bay m 1099 also markedly retarded the appearance of the peak postprandial blood glucose concentration, which indicates delayed carbohydrate absorption. Serum insulin levels, documented as incremental AUCs of the serum insulin excursions, were not reduced dose dependently, because of the impaired insulin secretory capacity of the patients.